IASLC World Conference on Lung Cancer

Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.

Final analysis of the phase 3 IMpower030 trial showed a median EFS of 62.8 months versus 34.9 months with placebo plus chemotherapy in stage IIB to IIIB disease.

First data from the phase 1B/2 BNT324-01 trial pair a PD-L1 and VEGF-A bispecific antibody with a B7H3-directed ADC in patients with SCLC.

Every-3-week and every-4-week tarlatamab regimens produced ORRs of 31% and 27% vs 40% with standard bi-weekly dosing in the phase 2 DeLLphi-309 trial.

The dose-finding DeLLphi-308 trial showed promising results for a more convenient administration of tarlatamab in patients with ES-SCLC.

The phase 3 LONESTAR trial was closed early for futility after added local consolidative therapy showed no OS or PFS benefit, including in oligometastatic disease.

Grant outlines open questions in perioperative NSCLC, from neoadjuvant sequencing and adjuvant selection to whether ctDNA is ready for practice.

A hematology-oncology fellow explains how trainees can use poster walks, follow-up contact, and review articles to find mentors and generate research questions.

D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.

Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.

Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.

Firmonertinib led to responses with a tolerable safety profile in frontline EGFR L858R–mutated NSCLC.

Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.

The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.

Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.

Perioperative tislelizumab plus chemotherapy showed sustained OS and EFS improvement vs chemotherapy in resectable NSCLC.

The SEZ6-targeting ADC ABBV-706 generated durable efficacy outcomes comparable with those of first-line SOC in patients with relapsed/refractory SCLC.

A correlation between ctDNA negativity in the post-surgical MRD window and improved RFS and OS was observed with the Signatera Genome assay in NSCLC.